Analysts forecast that Aileron Therapeutics Inc (NASDAQ:ALRN) will announce earnings of ($0.58) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.65). Aileron Therapeutics posted earnings of ($0.43) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 34.9%. The business is scheduled to issue its next earnings results on Thursday, November 8th.

On average, analysts expect that Aileron Therapeutics will report full-year earnings of ($2.16) per share for the current financial year, with EPS estimates ranging from ($2.37) to ($1.95). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.15) per share, with EPS estimates ranging from ($2.71) to ($1.63). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04).

ALRN has been the topic of several research reports. Zacks Investment Research upgraded shares of Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research note on Tuesday, July 10th. ValuEngine upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th.

In other news, major shareholder Bioventures Ltd Novartis sold 31,300 shares of the stock in a transaction on Tuesday, July 24th. The shares were sold at an average price of $4.25, for a total transaction of $133,025.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Apple Tree Partners Ii Lp sold 9,532 shares of the stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $5.32, for a total transaction of $50,710.24. The disclosure for this sale can be found here. In the last quarter, insiders acquired 6,000 shares of company stock worth $32,290 and sold 242,150 shares worth $1,223,406. 16.10% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in Aileron Therapeutics stock. Millennium Management LLC purchased a new position in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 18,585 shares of the company’s stock, valued at approximately $151,000. Millennium Management LLC owned about 0.13% of Aileron Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.79% of the company’s stock.

Aileron Therapeutics stock remained flat at $$2.44 during trading hours on Tuesday. 59,896 shares of the company’s stock traded hands, compared to its average volume of 75,383. The company has a current ratio of 5.85, a quick ratio of 9.16 and a debt-to-equity ratio of 0.10. Aileron Therapeutics has a 1 year low of $2.18 and a 1 year high of $15.48.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with's FREE daily email newsletter.